Facebook
Twitter
LinkedIn
Forward
Clinical Controversies in Pulmonary Hypertension: A Pro/Con Debate
Presented as three debates, this interactive module explores the controversies in the diagnosis and management of Pulmonary Arterial Hypertension (PAH). Our understanding and adoption of appropriate clinical approaches to manage PAH has greatly improved over recent decades; however, numerous clinical questions remain about how patients should be diagnosed and treated. The three debates demystify the controversies, improve medical knowledge, and promote better patient care and outcomes.
- Debate 1: Gomberg-Maitland and Kiely: Right Heart Catheterization vs. Non-Invasive Imaging for PH Patient Follow-Up
- Debate 2: Preston and Sitbon: Initial Triple Combination Therapy vs. Sequential Therapy in PAH Patients
- Debate 3: Lang and Kerr: Riociguat for CTEPH Patients
This course is an edited and enhanced recording of the ATS 2021 International Conference session with the same name.
Target Audience
Pulmonologists, critical care specialists, translational researchers, and clinicians
Learning Objectives
After successfully completing this module, learners will be able to:
- Summarize current clinical controversies in the diagnosis and management of PAH
- Better diagnose PAH and differentiate it from pulmonary venous hypertension
- Recognize the indications for testing RV reserve in patients with PAH
| Name | Title | Institution | Role | Relationship |
| Mardi Gomberg-Maitland, MD | Physician | George Washington University Health & Medical Sciences | Presenter, Debate 1 | None |
| David Kiely, MD | Physician | The University of Sheffield | Presenter, Debate 1 | Janssen: Speaker/faculty - non-promotional purpose, Research - investigator initiated Janssen: Advisory Committee - non-promotional Acceleron: Advisory Committee - non-promotional MSD: Speaker/faculty - non-promotional purpose, Advisory Committee - non-promotional GSK: Research - investigator initiated |
| Ioana R. Preston, MD | Physician | Tufts Medical Center | Presenter, Debate 2 | Actelion: Research-industry initiated, e.g., clinical trial, Advisory Committee - non-promotional Acceleron: Research-industry initiated, e.g., clinical trial, Advisory Committee - non-promotional Bayer: Research-industry initiated, e.g., clinical trial Gilead: Consultant Liquidia: Advisory Committee - non-promotional PhaseBio: Research-industry initiated, e.g., clinical trial Pfizer: Data Safety and Monitoring Board United Therapeutics: Research-industry initiated, e.g., clinical trial, Advisory Committee - non-promotional Medscape: Speaker/faculty - non-promotional purpose MedEd: Speaker/faculty - non-promotional purpose |
| Oliver Sitbon, MD, PhD | Physician | French Reference Center for Pulmonary Hypertension | Presenter, Debate 2 | Janssen: Consultant MSD: Consultant Acceleron: Consultant Gossamer Bio: Consultant AOP Orphan: Consultant Ferrer: Consultant |
| Irene M. Lang, MD | Physician | Medical University of Vienna | Presenter, Debate 3 | Actelion: Research - investigator initiated AOPOrphan: Consultant United Therapeutics: Advisory Committee - non-promotional Neutrolis: Research - investigator initiated |
| Kim M. Kerr, MD | Clinical Professor of Medicine | University of California San Diego | Presenter, Debate 3 | Bayer: Research - investigator initiated Actelion: Consultant |
Accreditation Statement
The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Disclosure Declaration
It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships are present. To see the most recent policies regarding potential conflicts of interest as well as the mechanisms to resolve such conflicts, press the COI Policy link below.
This educational activity may include discussion of unapproved uses of a drug, product, or device. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions to Receive Credit
To earn credit for this course, follow these instructions:
- Launch and complete all modules by viewing every page in the module.
- After you complete the module(s), the post test will become available. You must pass the post these with a 70% score or better.
- Complete the Course Evaluation.
- Once you complete the modules, pass the post test and complete the evaluation, the system will grant you credit.
- To view your transcript and print your certificate, go to the My Account drop-down list. Then select Transcript.
Available Credit
- 1.50 AMA PRA Category 1 Credit(s)™The American Thoracic Society designates this for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Participation